Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Coming to “Grp(s)” with Senescence in the Alveolar Epithelium

Coming to “Grp(s)” with Senescence in the Alveolar Epithelium EDITORIALS 4. Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-ivacaftor in triple-combination modulator therapy, which has shown greater efficacy patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl than either dual combination and has been approved by the U.S. Food JMed 2015;373:1783–1784. and Drug Administration. With the approval of the triple-combination 5. Burgel P-R, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al.; drug, 90% of patients with CF will be eligible for a CFTR modulator French Cystic Fibrosis Reference Network Study Group. Real-life (13). It is plausible that in the not-too-distant future, most infants safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med 2020;201:188–197. diagnosed with CF will begin a highly effective CFTR modulator, 6. Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda such as the triple-combination treatment, shortly after birth, and G, et al.; VX-809 TRAFFIC and TRANSPORT Study Groups. Efficacy continue receiving it indefinitely. This possibility highlights the and safety of lumacaftor/ivacaftor combination therapy in patients continuing need for postmarketing observational analyses, such as with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med 2016;4: this http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Respiratory and Critical Care Medicine Pubmed Central

Coming to “Grp(s)” with Senescence in the Alveolar Epithelium

American Journal of Respiratory and Critical Care Medicine , Volume 201 (2) – Jan 15, 2020
3 pages

Loading next page...
 
/lp/pubmed-central/coming-to-grp-s-with-senescence-in-the-alveolar-epithelium-MRn3iE0NLQ

References (47)

Publisher
Pubmed Central
Copyright
Copyright © 2020 by the American Thoracic Society
ISSN
1073-449X
eISSN
1535-4970
DOI
10.1164/rccm.201910-2052ED
Publisher site
See Article on Publisher Site

Abstract

EDITORIALS 4. Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-ivacaftor in triple-combination modulator therapy, which has shown greater efficacy patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl than either dual combination and has been approved by the U.S. Food JMed 2015;373:1783–1784. and Drug Administration. With the approval of the triple-combination 5. Burgel P-R, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, et al.; drug, 90% of patients with CF will be eligible for a CFTR modulator French Cystic Fibrosis Reference Network Study Group. Real-life (13). It is plausible that in the not-too-distant future, most infants safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med 2020;201:188–197. diagnosed with CF will begin a highly effective CFTR modulator, 6. Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda such as the triple-combination treatment, shortly after birth, and G, et al.; VX-809 TRAFFIC and TRANSPORT Study Groups. Efficacy continue receiving it indefinitely. This possibility highlights the and safety of lumacaftor/ivacaftor combination therapy in patients continuing need for postmarketing observational analyses, such as with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med 2016;4: this

Journal

American Journal of Respiratory and Critical Care MedicinePubmed Central

Published: Jan 15, 2020

There are no references for this article.